Skip to main content
Clinical Trials/NCT01990456
NCT01990456
Unknown
Not Applicable

Strategies for Optimal Lung Ventilation in ECMO for ARDS: The SOLVE ARDS Study

University of Toronto1 site in 1 country20 target enrollmentSeptember 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Respiratory Distress Syndrome, Adult
Sponsor
University of Toronto
Enrollment
20
Locations
1
Primary Endpoint
Ventilator-Induced Lung Injury (VILI) in patients with ARDS on ECMO ventilated with different strategies (tidal ventilation, CPAP, ZEEP), as measured by Serum Cytokines
Last Updated
11 years ago

Overview

Brief Summary

Due to lack of studies on mechanical ventilation strategies in patients with severe Acute Respiratory Distress Syndrome (ARDS) supported with Veno-Venous Extra-Corporeal Membrane Oxygenation (VV ECMO), ventilator settings in this patient population are set arbitrarily.

In this two-phases prospective, interventional, pilot study we hope to gain physiologically relevant data on two aspects of mechanical ventilation in patients with severe ARDS supported with VV ECMO: (1) the use of tidal ventilation and (2) the level of Positive End-Expiratory Pressure (PEEP).

  1. PHASE 1: impact of tidal ventilation on VILI (10 patients) We hypothesized that a CPAP strategy that minimizes end-tidal pulmonary stress and strain mitigates VILI compared to the current mechanical ventilation practice that employs tidal ventilation in patients with severe ARDS on ECMO.

    In this first phase we will test whether administering a distending inspiratory pressure to produce tidal ventilation is superior to a strategy where only continuous positive airway pressure (CPAP) is applied for ventilation induced lung injury (VILI) mitigation, as assessed by its impact on biotrauma (serum cytokines) and physiologic measurements.

  2. PHASE 2: impact of PEEP on VILI (10 patients) We also hypothesized that adjusting PEEP to maximize respiratory system compliance reduces VILI in patients with severe ARDS on ECMO.

In the second phase we will therefore gain more insight as to whether a strategy that utilizes a PEEP level that correspond to best compliance is beneficial over Zero End-Expiratory Pressure (ZEEP). We will test the impact of both strategies on biotrauma (serum cytokines), physiologic parameters, and right ventricular function (transesophageal echocardiographic assessment).

Because ARDS patients supported with VV ECMO can be hemodynamically unstable, the use of imaging techniques that require transport, such as computed tomography, is limited. Therefore, bedside imaging techniques, such as pleural and lung ultrasound (PLUS) and focused bedside cardiac ultrasonography, are important tools for clinicians who care for these patients. This study will allow us to learn whether these techniques are feasible and valid in this patient population.

Furthermore, the knowledge gained from this study will allow us to assess the rationale and feasibility of performing a similar larger, randomized study in the future.

Registry
clinicaltrials.gov
Start Date
September 2014
End Date
December 2015
Last Updated
11 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Eddy Fan

MD, PhD

University of Toronto

Eligibility Criteria

Inclusion Criteria

  • Severe ARDS (Berlin Definition)
  • VV ECMO \< 72 hours
  • Endotracheal intubation or tracheostomy

Exclusion Criteria

  • Thoracic surgery/lung transplantation during the current hospitalization
  • Contraindications to a RM (MAP \< 60 mmHg despite administration of fluids and vasopressors; Active air leak through a thoracostomy tube; Pneumothorax, or subcutaneous or mediastinal emphysema, (if chest tube has not been inserted))
  • Contraindications to TEE
  • Age \< 16 years

Outcomes

Primary Outcomes

Ventilator-Induced Lung Injury (VILI) in patients with ARDS on ECMO ventilated with different strategies (tidal ventilation, CPAP, ZEEP), as measured by Serum Cytokines

Time Frame: 1 hour after initiation of each experimental ventilation strategy

Secondary Outcomes

  • Feasibility (patient recruitment, protocol adherence, physiologic tolerability)(At overall study completion (i.e., 24 months from study start or after enrolment of last patient))
  • Feasibility of lung ultrasound in patients with severe ARDS on ECMO(30 minutes after initiation of experimental CPAP/ZEEP strategy)
  • Feasibility and validity of focused cardiac ultrasound, as compared to TEE as gold standard, in the assessment of RV function in patients with ARDS on ECMO(30 minutes after initiation of experimental CPAP/ZEEP strategy)
  • Impact of a CPAP strategy (PEEP set at best compliance and at ZEEP) in patients with severe ARDS on ECMO, as measured by transesophageal echocardiography (TEE)(30 minutes after initiation of experimental CPAP/ZEEP strategy)

Study Sites (1)

Loading locations...

Similar Trials